Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Применение ацеклофенака (Аэртал) на ранних стадиях гонартроза
________________________________________________
Zagorodniy N.V., Ivashkin A.N., Zakirova A.R., Skipenko T.О. Use of aceclofenac (Aertal) in early stages arthrosis of the knee joint. Consilium Medicum. 2016; 18 (8): 42–45. DOI: 10.26442/2075-1753_2016.8.42-45
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Результаты данного исследования выявили более благоприятный профиль безопасности группы В (Аэртал®) по сравнению с группой A (диклофенак) на фоне практически равнозначной эффективности препаратов обеих групп. При этом Аэртал® обладает значительно лучшей желудочно-кишечной переносимостью, чем диклофенак. Исходя из представленных данных, можно констатировать, что ключевым моментом в выборе нестероидного противовоспалительного препарата врачом-ортопедом являются его высокая клиническая эффективность, безопасность, а также хорошая переносимость.
Ключевые слова: гонартроз, коленный сустав, ацеклофенак (Аэртал).
________________________________________________
The results of this study showed a favorable safety profile in the group B (Aertal®) compared with group A (diclofenac), against the background of almost equivalent efficacy of both groups. Thus Aertal® has much better gastrointestinal tolerability than diclofenac. Based on the data, it can be stated that the key issue in choosing NSAID orthopedic surgeon is its high clinical efficacy, safety, and well-tolerated.
Key words: arthrosis, knee joint, aceclofenac (Aertal).
2. Ogata Y, Mabuchi Y, Yoshida M et al. Purified Human Synovium Mesenchymal Stem Cells as a Good Resource for Cartilage Regeneration. PLoS ONE 2015; 10 (6).
3. Matsukura Y, Muneta T, Tsuji K et al. Mouse synovial mesenchymal stem cells increase in yield with knee inflammation. J Orthop Res 2015; 33: 246–53.
4. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage 2013; 21: 16–21. doi: 10.1016/j.joca.2012.11.012.
5. Jakobsen RB, Engebretsen L, Slauterbeck JR. An Analysis of the Quality of Cartilage Repair Studies. J Bone Joint Surg Am 2014; 87 (10): 2232–9.
6. Anthony J. Ferretti, DO. Osteoarthritis of the Knee: Pill, Needle, or Knife. MHSA Primary Care 2015 LECOM Summer CME.
7. Lanas A, Ferrandez A. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention. Chin J Dig Dis 2006; 7 (3): 127–33.
8. Ward DE, Veys EM, Bowdker JM, Roma J. Comparison of aceclofenac with diclofenac in the treatment of osteoarthrosis. Clin Rheumatol 1995; 14: 656–62.
9. Somashekar PL, Sanjay Pai PN, Gopalkrishna Rao. Synthesis and Characterization of Specified Impurities of Aceclofenac. Chem Sci Trans 2013; 2 (3): 813–20.
10. Brandt KD. The mechanism of action of nonsteroidal anti–inflammatory drugs. J Rheum 1991; 18: 120–1.
11. Чичасова Н.В. Лечение остеоартроза: влияние на хрящевую ткань различных противовоспалительных препаратов. Рус. мед. журн. 2005; 13 (8): 539–43. /
Chichasova N.V. Lechenie osteoartroza: vliianie na khriashchevuiu tkan' razlichnykh protivovospalitel'nykh preparatov. Rus. med. zhurn. 2005; 13 (8): 539–43. [in Russian]
12. Hаskinsson EC, Irani M, Murray F. A large prospective open-label, multi-centre SAMM study, comparing the safety of aceclofenac with diclofenac in patients with rheumatic disease. Eur J Rheumatol Inflam 2000; 17: 1–7.
13. Dooley M, Spencer CM, Dunn CJ et al. Aceclofenac. A reappraisal of its use in the management of pain and rheumatic disease. Drugs 2001; 61 (9): 1351–78.
14. Pasero G, Ruju G, Macolongo R et al. Aceclofenac versus naproхen in the treatment of ankylosing spondylitis: a double-blend, controlled study. Curr Nher Res 1994; 55: 833–42.
15. Perez Busquiner M, Calero E, Rodriguez M et al. Comparison of aceclofenac with piroxicam in the treatment of osteosrthrosis. Clin Rheumatol 1997; 16: 154–9.
16. Ward DE, Veys EM, Bowdler JM, Roma J. Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. Clin Rheumatol 1995; 14 (6): 656–62.
17. Lemmel EM, Leeb B, De Bast J, Aslanidis S. Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the management of inflammatory pain. Curr Med Res Opin 2002; 18 (3): 146–53.
________________________________________________
1. Naoshi F, Yoshinari M, Masahiro N et al. Zonal gene expression of chondrocytes in osteoarthritic cartilage. Arthritis Rheum 2008; 58 (12): 3843–53.
2. Ogata Y, Mabuchi Y, Yoshida M et al. Purified Human Synovium Mesenchymal Stem Cells as a Good Resource for Cartilage Regeneration. PLoS ONE 2015; 10 (6).
3. Matsukura Y, Muneta T, Tsuji K et al. Mouse synovial mesenchymal stem cells increase in yield with knee inflammation. J Orthop Res 2015; 33: 246–53.
4. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage 2013; 21: 16–21. doi: 10.1016/j.joca.2012.11.012.
5. Jakobsen RB, Engebretsen L, Slauterbeck JR. An Analysis of the Quality of Cartilage Repair Studies. J Bone Joint Surg Am 2014; 87 (10): 2232–9.
6. Anthony J. Ferretti, DO. Osteoarthritis of the Knee: Pill, Needle, or Knife. MHSA Primary Care 2015 LECOM Summer CME.
7. Lanas A, Ferrandez A. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention. Chin J Dig Dis 2006; 7 (3): 127–33.
8. Ward DE, Veys EM, Bowdker JM, Roma J. Comparison of aceclofenac with diclofenac in the treatment of osteoarthrosis. Clin Rheumatol 1995; 14: 656–62.
9. Somashekar PL, Sanjay Pai PN, Gopalkrishna Rao. Synthesis and Characterization of Specified Impurities of Aceclofenac. Chem Sci Trans 2013; 2 (3): 813–20.
10. Brandt KD. The mechanism of action of nonsteroidal anti–inflammatory drugs. J Rheum 1991; 18: 120–1.
11. Chichasova N.V. Lechenie osteoartroza: vliianie na khriashchevuiu tkan' razlichnykh protivovospalitel'nykh preparatov. Rus. med. zhurn. 2005; 13 (8): 539–43. [in Russian]
12. Hаskinsson EC, Irani M, Murray F. A large prospective open-label, multi-centre SAMM study, comparing the safety of aceclofenac with diclofenac in patients with rheumatic disease. Eur J Rheumatol Inflam 2000; 17: 1–7.
13. Dooley M, Spencer CM, Dunn CJ et al. Aceclofenac. A reappraisal of its use in the management of pain and rheumatic disease. Drugs 2001; 61 (9): 1351–78.
14. Pasero G, Ruju G, Macolongo R et al. Aceclofenac versus naproхen in the treatment of ankylosing spondylitis: a double-blend, controlled study. Curr Nher Res 1994; 55: 833–42.
15. Perez Busquiner M, Calero E, Rodriguez M et al. Comparison of aceclofenac with piroxicam in the treatment of osteosrthrosis. Clin Rheumatol 1997; 16: 154–9.
16. Ward DE, Veys EM, Bowdler JM, Roma J. Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. Clin Rheumatol 1995; 14 (6): 656–62.
17. Lemmel EM, Leeb B, De Bast J, Aslanidis S. Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the management of inflammatory pain. Curr Med Res Opin 2002; 18 (3): 146–53.
ФГАОУ ВО Российский университет дружбы народов. 117198, Россия, Москва, ул. Миклухо-Маклая, д. 6;
ГБУЗ Городская клиническая больница №31 Департамента здравоохранения г. Москвы. 119415, Россия, Москва, ул. Лобачевского, д. 42
*arthro@mail.ru
________________________________________________
People’s Friendship University of Russia. 117198, Russian Federation, Moscow, ul. Miklukho-Maklaya, d. 6;
City Clinical Hospital №31 of the Department of Health of Moscow. 119415, Russian Federation, Moscow, ul. Lobachevskogo, d. 42
*arthro@mail.ru